Dupilumab Efficacy in Type 2 Inflammatory Asthma: Liberty Asthma QUEST Study

I. Pavord (Oxford, United Kingdom), J. Fitzgerald (Vancouver, Canada), G. Brusselle (Ghent, Belgium), S. Wenzel (Pittsburgh, United States of America), K. Rabe (Grosshandsdorf and Kiel, Germany), W. Busse (Madison, United States of America), A. Papi (Ferrara, Italy), M. Rice (Cambridge, United States of America), Y. Deniz (Tarrytown, United States of America), P. Rowe (Birdgewater, United States of America), N. Amin (Tarrytown, United States of America), N. Graham (Tarrytown, United States of America), A. Teper (Birdgewater, United States of America)

Source: International Congress 2019 – Precision meets immunology in treatment of airway diseases
Session: Precision meets immunology in treatment of airway diseases
Session type: Oral Presentation
Number: 3807

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
I. Pavord (Oxford, United Kingdom), J. Fitzgerald (Vancouver, Canada), G. Brusselle (Ghent, Belgium), S. Wenzel (Pittsburgh, United States of America), K. Rabe (Grosshandsdorf and Kiel, Germany), W. Busse (Madison, United States of America), A. Papi (Ferrara, Italy), M. Rice (Cambridge, United States of America), Y. Deniz (Tarrytown, United States of America), P. Rowe (Birdgewater, United States of America), N. Amin (Tarrytown, United States of America), N. Graham (Tarrytown, United States of America), A. Teper (Birdgewater, United States of America). Dupilumab Efficacy in Type 2 Inflammatory Asthma: Liberty Asthma QUEST Study. 3807

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: